Two Securities Suspended Ahead of Paradigm Trial Update
2 min read
9:01am on Wednesday 23rd of September, 2026 AEST ~9am, 23rd Sept, 26
Paradigm Biopharmaceuticals has secured a voluntary suspension of its ASX securities while it prepares to release interim analysis results from its PARA_OA_012 Phase 3 trial. The announcement gives no indication whether the clinical readout is favourable or unfavourable, with trading potentially resuming on 28 September subject to ASX approval.
- PAR and PAROB suspended from quotation from 23 September
- Suspension pending PARA_OA_012 Phase 3 interim analysis results
- Company requested the suspension to manage continuous disclosure obligations
- Trading could resume on 28 September, subject to ASX agreement
- Announcement provides no detail on the results or their direction
Paradigm Biopharmaceuticals Limited (ASX:PAR) has paused trading in both its ordinary securities and options ahead of a clinical announcement that could materially shape expectations for its business. ASX suspended PAR and PAROB from quotation on 23 September at Paradigm’s request, pending the release of interim analysis results from the PARA_OA_012 Phase 3 trial.
Trading Halted Before Phase 3 Readout
The company said the suspension was intended to help it manage its continuous disclosure obligations while it prepares the announcement. That wording signals that the interim analysis is considered sufficiently important to warrant a controlled release before normal trading resumes, but the filing does not disclose the result, its expected direction or any clinical measurements.
That leaves the market with a significant information gap. The upcoming announcement may provide detail on the interim analysis methodology, efficacy and safety findings, but none of those outcomes can be inferred from the suspension itself. A halt before a major clinical update is a procedural safeguard, not evidence that the trial has succeeded or failed.
Resumption Date Remains Conditional
Paradigm has asked for the suspension to remain in place until the interim-results announcement is released, or until trading begins on Monday 28 September. The latter date is conditional on ASX agreeing to reinstate the securities to quotation, so it is not a guaranteed resumption date.
For shareholders, the next decisive document is therefore the clinical announcement rather than the suspension notice. The key questions will be what the interim analysis shows, how the company describes the trial’s implications and whether the results alter the path for PARA_OA_012. Until that information is released, the suspension preserves uncertainty rather than resolving it.
Bottom Line?
The suspension sets the stage for a high-impact clinical update, but the filing itself offers no basis for judging whether the interim results will help or hurt Paradigm’s case.
Questions in the middle?
- What efficacy and safety findings will Paradigm disclose from the interim analysis?
- Will the interim results support continuation of PARA_OA_012 on its current path?
- When will ASX approve reinstatement, and will trading resume by 28 September?
